Investigational drug · Phase 3
anzutresgene autoleucel
Also called: IMA203 Product, IMA203 product- flat dose, IMA203
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "anzutresgene autoleucel"
First trial start
2019
May 14, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "anzutresgene autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult
- Cancer
- Melanoma, Cutaneous Malignant
- Mucosal Melanoma
Largest trials
Live from ClinicalTrials.gov: studies naming "anzutresgene autoleucel" as an intervention, largest first.
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaPivotal-lookingRecruiting
Immatics US, Inc.Industry
NCT06743126 · 450 participants (planned) · Start Jan 14, 2025 · Primary completion Jan 2028
Drug: IMA203; nivolumab plus relatlimab and 9 more · For: Melanoma, Cutaneous Malignant; Mucosal Melanoma
Sites: Phoenix, Arizona; Scottsdale, Arizona; Duarte, California · 71 sites in all
Immatics US, Inc.Industry
NCT03686124 · 375 participants (planned) · Start May 14, 2019 · Primary completion Dec 2028
Drug: IMA203 Product; IMA203 product- flat dose and 2 more · For: Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult and 1 more
Sites: Stanford, California; Aurora, Colorado; Miami, Florida · 21 sites in all
Immatics US, Inc.Industry
NCT06946225 · 15 participants (planned) · Start Jul 25, 2025 · Primary completion Aug 2029
Drug: IMA203; mRNA-4203 · For: Cutaneous Melanoma; Synovial Sarcoma
Sites: San Francisco, California; Boston, Massachusetts; New York, New York · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Top advances of the year in autologous cellular therapy in melanoma and solid tumors.
Loo K, Betof AS · Cancer 2026
- Shared PRAME epitopes are T-cell targets in NUT carcinoma.
Jensen JL, Peterson SK, Sambade MJ, et al. · J Immunother Cancer 2026
- Shared PRAME Epitopes are T-Cell Targets in NUT Carcinoma.
Jensen JL, Peterson SK, Sambade M, et al. · bioRxiv 2025
- Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.
Wermke M, Araujo DM, Chatterjee M, et al. · Nat Med 2025
Also in development for Refractory Cancer
- Checkpoint InhibitorPhase 22 trials
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- Monoclonal antibodyPhase 22 trials
Immunocore Ltd · Cancer, HLA-A*02:01-positive, Refractory Cancer
- HST-1011Phase 21 trial
HotSpot Therapeutics, Inc · Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- IMA401Phase 21 trial
Immatics Biotechnologies GmbH · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
- IMA402Phase 21 trial
Immatics Biotechnologies GmbH · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.